| Nicholas Panaro, MD | |
|
664 Stoneleigh Ave Ste 300, Carmel, NY 10512-3990 | |
| (845) 278-8400 | |
| (845) 278-4326 |
| Full Name | Nicholas Panaro |
|---|---|
| Gender | Male |
| Speciality | Specialist |
| Location | 664 Stoneleigh Ave Ste 300, Carmel, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689606501 | NPI | - | NPPES |
| 260051518 | Other | NY | RAILROAD MEDICARE |
| P00017559 | Other | NY | RAILROAD MEDICARE |
| WCJ511 | Other | NY | MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 61173 (Connecticut) | Secondary |
| 174400000X | Specialist | 193022 (New York) | Primary |
| Entity Name | Somers Orthopaedic Surgery & Sports Medicine Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427533959 PECOS PAC ID: 9638061674 Enrollment ID: O20190306001161 |
News Archive
Researchers at Mount Sinai School of Medicine have discovered a new mechanism of activation of a pathway known to be implicated in many cancers.
Black patients from disadvantaged neighborhoods were significantly more likely to die within five years of surviving a heart attack compared with Black heart attack patients from wealthier neighborhoods and white patients of any socioeconomic means who survive a heart attack, according to a study being presented at the American College of Cardiology's 70th Annual Scientific Session.
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
A new report published in the Feb. 28 issue of the Journal of the American Medical Association points to a significantly higher burden of diabetes-related complications in adolescents and young adults with type 2 diabetes compared to type 1 diabetes, with greater health complications in minority youth.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Panaro, MD 664 Stoneleigh Ave Ste 300, Carmel, NY 10512-3990 Ph: (845) 278-8400 | Nicholas Panaro, MD 664 Stoneleigh Ave Ste 300, Carmel, NY 10512-3990 Ph: (845) 278-8400 |
News Archive
Researchers at Mount Sinai School of Medicine have discovered a new mechanism of activation of a pathway known to be implicated in many cancers.
Black patients from disadvantaged neighborhoods were significantly more likely to die within five years of surviving a heart attack compared with Black heart attack patients from wealthier neighborhoods and white patients of any socioeconomic means who survive a heart attack, according to a study being presented at the American College of Cardiology's 70th Annual Scientific Session.
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
A new report published in the Feb. 28 issue of the Journal of the American Medical Association points to a significantly higher burden of diabetes-related complications in adolescents and young adults with type 2 diabetes compared to type 1 diabetes, with greater health complications in minority youth.
› Verified 2 days ago